Optimization of statistical single subject analysis of brain FDG PET for the prognosis of mild cognitive impairment-to-Alzheimer's disease conversion

Journal of Alzheimer's Disease

Volumn 49, Issue 4, 2015, Pages 945-959

  Lange, Catharina ^a   Suppa, Per ^a,b   Frings, Lars ^c   Brenner, Winfried ^a   Spies, Lothar ^b   Buchert, Ralph ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b JUNG DIAGNOSTICS GMBH   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Alzheimer's Disease Neuroimaging Initiative; F 18 fluorodeoxyglucose; intensity scaling; mild cognitive impairment; positron emission tomography; processing pipeline; prognosis; single subject analysis; statistical parametric mapping; template

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; RADIOPHARMACEUTICAL AGENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; PARAMETRIC TEST; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROGNOSIS; VOXEL BASED MORPHOMETRY; AREA UNDER THE CURVE; BRAIN; COGNITIVE DYSFUNCTION; COMPUTER ASSISTED DIAGNOSIS; DIAGNOSTIC IMAGING; DISEASE COURSE; FOLLOW UP; METABOLISM; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; VALIDATION STUDY;

AGED; ALZHEIMER DISEASE; AREA UNDER CURVE; BRAIN; COGNITIVE DYSFUNCTION; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; GLUCOSE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOPHARMACEUTICALS; ROC CURVE;

EID: 84953728818     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150814     Document Type: Article

References (57)

1. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. (1979). Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: Validation of method. Ann Neurol. 6, 371-388.
2. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. (1997). Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol. 42, 85-94.
3. Herholz K. (2010). Cerebral glucose metabolism in preclinical, and prodromal Alzheimer's disease. Expert Rev Neurother. 10, 1667-1673.
4. Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, Reiman EM, Holthoff V, Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ. (2008). Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med. 49, 390-398.
5. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE. (1983). Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr. 7, 590-598.
6. Silverman DH. (2004). Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: Comparison with perfusion SPECT, and with clinical evaluations lacking nuclear imaging. J Nucl Med. 45, 594-607.
7. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME. (2001). Positron emission tomography in evaluation of dementia: Regional brain metabolism, and long-Term outcome. JAMA. 286, 2120-2127.
8. Jagust W. (2006). Positron emission tomography, and magnetic resonance imaging in the diagnosis, and prediction of dementia. Alzheimers Dement. 2, 36-42.
9. Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, DeCarli CS, Turner RS, Koeppe RA, Higdon R, Minoshima S. (2007). FDG-PET improves accuracy in distinguishing frontotemporal dementia, and Alzheimer's disease. Brain. 130, 2616-2635.
10. Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. (2001). Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 50, 358-365.
11. Foster NL, Wang AY, Tasdizen T, Fletcher PT, Hoffman JM, Koeppe RA. (2008). Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease. Alzheimers Dement. 4, S29-S36.
12. Jagust WJ, Haan MN, Eberling JL, Wolfe N, Reed BR. (1996). Functional imaging predicts cognitive decline in Alzheimer's disease. J Neuroimaging. 6, 156-160.
13. Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, Phelps CH. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279.
14. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, Phelps CH. (2011). The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 263-269.
15. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O'Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. (2007). Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol. 6, 734-746.
16. Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL. (2014). Advancing research diagnostic criteria for Alzheimer's disease: The IWG-2 criteria. Lancet Neurol. 13, 614-629.
17. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. (1995) A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med. 36, 1238-1248.
18. Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE. (2007). Statistical Parametric Mapping: The Analysis of Functional Brain Images, Academic Press
19. Burdette JH, Minoshima S, Vander Borght T, Tran DD, Kuhl DE. (1996). Alzheimer disease: Improved visual interpretation of PET images by using three-dimensional stereotaxic surface projections. Radiology. 198, 837-843.
20. Varrone A, Asenbaum S, Vander Borght T, Booij J, Nobili F, Nagren K, Darcourt J, Kapucu OL, Tatsch K, Bartenstein P, Van Laere K, European Association of Nuclear Medicine Neuroimaging, Committee. (2009). EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 36, 2103-2110.
21. Waxman AD, Herholz K, Lewis DH, Herscovitch P, Minoshima S, Ichise M, Drzezga AE, Devous MD, Mountz JM. (2009). Society of Nuclear Medicine procedure guideline for FDG PET brain imaging. Society of Nuclear Medicine, Reston, VA.
22. Frackowiak RSJ, Friston KJ, Frith CD, Dolan RJ, Price CJ, Zeki S, Ashburner JT, Penny WD, eds. (2004). Human Brain Function, Academic Press, San Diego
23. Acton PD, Friston KJ. (1998). Statistical parametric mapping in functional neuroimaging: Beyond PET, and fMRI activation studies. Eur J Nucl Med. 25, 663-667.
24. Andersson JL, Vagnhammar BE, Schneider H. (1995). Accurate attenuation correction despite movement during PET imaging. J Nucl Med. 36, 670-678.
25. Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, Gilardi MC, Frisoni G, Friston K, Ashburner J, Perani D, Consortium EADC-PET. (2014) A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 12, 575-593.
26. Ashburner J, Friston KJ. (2005). Unified segmentation. Neuroimage. 26, 839-851.
27. Lemaitre H, Crivello F, Grassiot B, Alperovitch A, Tzourio C, Mazoyer B. (2005). Age-, and sex-related effects on the neuroanatomy of healthy elderly. Neuroimage. 26, 900-911.
28. Suppa P, Hampel H, Spies L, Fiebach JB, Dubois B, Buchert R. (2015). Fully automated atlas-based hippocampus volumetry for clinical routine: Validation in subjects with mild cognitive impairment from the ADNI cohort. J Alzheimers Dis. 44, 183-193.
29. Suppa P, Anker U, Spies L, Bopp I, Ruegger-Frey B, Klaghofer R, Gocke C, Hampel H, Beck S, Buchert R. (2014). Fully automated atlas-based hippocampal volumetry for detection of Alzheimer's disease in a memory clinic setting. J Alzheimers Dis. 44, 183-193.
30. Stamatakis EA, Glabus MF, Wyper DJ, Barnes A, Wilson JT. (1999). Validation of statistical parametric mapping (SPM) in assessing cerebral lesions: A simulation study. Neuroimage. 10, 397-407.
31. Yakushev I, Hammers A, Fellgiebel A, Schmidtmann I, Scheurich A, Buchholz HG, Peters J, Bartenstein P, Lieb K, Schreckenberger M. (2009). SPM-based count normalization provides excellent discrimination of mild Alzheimer's disease, and amnestic mild cognitive impairment from healthy aging. Neuroimage. 44, 43-50.
32. Minoshima S, Frey KA, Foster NL, Kuhl DE. (1995). Preserved pontine glucose metabolism in Alzheimer disease: A reference region for functional brain image (PET) analysis. J Comput Assist Tomogr. 19, 541-547.
33. Wenzel F, Young S, Wilke F, Apostolova I, Arlt S, Jahn H, Thiele F, Buchert R. (2010). B-spline-based stereotactical normalization of brain FDG PET scans in suspected neurodegenerative disease: Impact on voxel-based statistical single-subject analysis. Neuroimage. 50, 994-1003.
34. Andersson JL. (1997). How to estimate global activity independent of changes in local activity. Neuroimage. 6, 237-244.
35. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. (2003). An automated method for neuroanatomic, and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 19, 1233-1239.
36. Muhlau M, Wohlschlager AM, Gaser C, Valet M, Weindl A, Nunnemann S, Peinemann A, Etgen T, Ilg R. (2009). Voxelbased morphometry in individual patients: A pilot study in early Huntington disease. AJNR Am J Neuroradiol. 30, 539-543.
37. Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frolich L, Schonknecht P, Ito K, Mielke R, Kalbe E, Zundorf G, Delbeuck X, Pelati O, Anchisi D, Fazio F, Kerrouche N, Desgranges B, Eustache F, Beuthien-Baumann B, Menzel C, Schroder J, Kato T, Arahata Y, Henze M, Heiss WD. (2002). Discrimination between Alzheimer dementia, and controls by automated analysis of multicenter FDG PET. Neuroimage. 17, 302-316.
38. DeLong ER, DeLong DM, Clarke-Pearson DL. (1988). Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics. 44, 837-845.
39. Youden WJ. (1950). Index for rating diagnostic tests. Cancer. 3, 32-35.
40. Kohavi R (1995)Astudy of cross-validation, and bootstrap for accuracy estimation, and model selection. International Joint Conference on Artificial Intelligence (IJCAI
41. Buchert R, Wilke F, Chakrabarti B, Martin B, Brenner W, Mester J, Clausen M. (2005). Adjusted scaling ofFDGpositron emission tomography images for statistical evaluation in patients with suspected Alzheimer's disease. J Neuroimaging. 15, 348-355.
42. Herholz K, Perani D, Salmon E, Franck G, Fazio F, Heiss WD, Comar D. (1993). Comparability of FDG PET studies in probable Alzheimer's disease. J Nucl Med. 34, 1460-1466.
43. Yakushev I, Landvogt C, Buchholz HG, Fellgiebel A, Hammers A, Scheurich A, Schmidtmann I, Gerhard A, Schreckenberger M, Bartenstein P. (2008). Choice of reference area in studies of Alzheimer's disease using positron emission tomography with fluorodeoxyglucose-F18. Psychiatry Res. 164, 143-153.
44. Borghammer P, Jonsdottir KY, Cumming P, Ostergaard K, Vang K, Ashkanian M, Vafaee M, Iversen P, Gjedde A. (2008). Normalization in PET group comparison studies-The importance of a valid reference region. Neuroimage. 40, 529-540.
45. Borghammer P, Cumming P, Aanerud J, Gjedde A. (2009). Artefactual subcortical hyperperfusion in PET studies normalized to global mean: Lessons from Parkinson's disease. Neuroimage. 45, 249-257.
46. Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, Gilardi MC, Frisoni G, Friston K, Ashburner J, Perani D, Consortium E-P. (2014) A standardized [(18)F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 12, 575-593.
47. Gispert JD, Pascau J, Reig S, Martinez-Lazaro R, Molina V, Garcia-Barreno P, Desco M. (2003). Influence of the normalization template on the outcome of statistical parametric mapping of PET scans. Neuroimage. 19, 601-612.
48. Martino ME, de Villoria JG, Lacalle-Aurioles M, Olazaran J, Cruz I, Navarro E, Garcia-Vazquez V, Carreras JL, Desco M. (2013). Comparison of different methods of spatial normalization of FDG-PET brain images in the voxel-wise analysis of MCI patients, and controls. Ann Nucl Med. 27, 600-609.
49. Worsley KJ, Marrett S, Neelin P, Evans AC. (1996). Searching scale space for activation in PET images. Hum Brain Mapp. 4, 74-90.
50. Rosenfeld A, Kak AC. (1982). Digital Picture Processing, Academic Press, New York
51. Arbizu J, Prieto E, Martinez-Lage P, Marti-Climent JM, Garcia-Granero M, Lamet I, Pastor P, Riverol M, Gomez-Isla MT, Penuelas I, Richter JA, Weiner MW, Alzheimer's Disease Neuroimaging I. (2013). Automated analysis of FDG PET as a tool for single-subject probabilistic prediction, and detection of Alzheimer's disease dementia. Eur J Nucl Med Mol Imaging. 40, 1394-1405.
52. Caroli A, Prestia A, Chen K, Ayutyanont N, Landau SM, Madison CM, Haense C, Herholz K, Nobili F, Reiman EM, Jagust WJ, Frisoni GB, Eadc-Pet Consortium N-D, Alzheimer's Disease Neuroimaging Initiative. (2012). Summary metrics to assess Alzheimer disease-related hypometabolic pattern with 18F-FDG PET: Head-To-head comparison. J Nucl Med. 53, 592-600.
53. Herholz K, Westwood S, Haense C, Dunn G. (2011). Evaluation of a calibrated (18)F-FDG PET score as a biomarker for progression in Alzheimer disease, and mild cognitive impairment. J Nucl Med. 52, 1218-1226.
54. Morbelli S, Brugnolo A, Bossert I, Buschiazzo A, Frisoni GB, Galluzzi S, van Berckel BN, Ossenkoppele R, Perneczky R, Drzezga A, Didic M, Guedj E, Sambuceti G, Bottoni G, Arnaldi D, Picco A, De Carli F, Pagani M, Nobili F. (2014). Visual versus semi-quantitative analysis of 18F-FDG-PET in amnestic MCI: An European Alzheimer's Disease Consortium (EADC) project. J Alzheimers Dis. 44, 815-826.
55. Chen K, Ayutyanont N, Langbaum JB, Fleisher AS, Reschke C, Lee W, Liu X, Bandy D, Alexander GE, Thompson PM, Shaw L, Trojanowski JQ, Jack CR Jr, Landau SM, Foster NL, Harvey DJ, Weiner MW, Koeppe RA, Jagust WJ, Reiman EM, Alzheimer's Disease Neuroimaging, Initiative. (2011). Characterizing Alzheimer's disease using a hypometabolic convergence index. Neuroimage. 56, 52-60.
56. Ritter K, Schumacher J, Weygandt M, Buchert R, Allefeld C, Haynes J-D, for the Alzheimer's Disease Neuroimaging Initiative. (2015). Multimodal prediction of conversion to Alzheimer's disease based on incomplete biomarkers. Alzheimers Dement (Amst) 1, 206-215.
57. Perani D, Della Rosa PA, Cerami C, Gallivanone F, Fallanca F, Vanoli EG, Panzacchi A, Nobili F, Pappata S, Marcone A, Garibotto V, Castiglioni I, Magnani G, Cappa SF, Gianolli L, Consortium E-P. (2014). Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neuroimage Clin. 6, 445-454.